Labyrinthitis Market Research Report- Global Forecast till 2023

Labyrinthitis Market Growth And Trends Analysis By Type (Autoimmune Labyrinthitis, Infective Labyrinthitis), Diagnosis (Blood Test, Magnetic Resonance Imaging (Mri) & Computed Tomography), And Treatment (Drug (Antibiotics), Therapy End-User - Global Forecast Till 2023

ID: MRFR/Pharma/3202-HCR | February 2021 | Region: Global | 110 pages

Market Synopsis of Global Lab


Labyrinthitis, also known as vestibular neuritis, is an inflammation of the inner ear or the nerves that connect the inner ear to the brain due to a variety of reasons such as infection by measles, mumps, trauma, autoimmune etc. Labyrinthitis shows various symptoms such as hearing loss, speech problems, double vision, abnormal gait, dizziness, nystagmus (rapid and undesired eye motion), vertigo, ringing in the ears, etc. Labyrinthitis is triggered by cold flu and occur as a single attack, or a series of attacks, which generally resolves on its own over three to six weeks.


The causes of labyrinthitis are upper respiratory infection such as common cold or flu, infection by herpes simplex type 1 virus, acute localized ischemia, pressure changes such as while flying or scuba diving, etc. Labyrinthitis affects approximately 35 cases per 1 million people per year across the globe and it is rising due to growing exposure to pathogenic agents. Labyrinthitis affects older population to a greater degree due to weak immunity and hearing problems.


Rising older population, increasing awareness and screening, developing healthcare and ENT centres, developing new drugs, especially the advancements in antibiotics are driving the market growth. Development of selective antibiotics for ear and nose infections such as streptomycin has driven the market growth. On the other hand, side effects and high cost of treatment and misdiagnosis may hinder the growth of the labyrinthitis market over the review period.


The global labyrinthitis market is expected to reach USD 2.5 billion by 2023 at a CAGR of ~ 3.2% during the forecast period 2017-2023.


Research Methodology
Labyrinthitis Market


Sources: Mayo Clinic, Healthline Media, MRFR Analysis


Intended Audience



  • Global labyrinthitis manufacturers & suppliers

  • Research and development (R&D) companies

  • Hospitals and clinics

  • Academic institutes and universities

Figure 1          Global Labyrinthitis Market by Types, 2016 (%)
GLobal Labyrinthitis Market

Segments


The global labyrinthitis market has been segmented on the basis of types, diagnosis, treatment, and end user.


Based on the types, the market has been segmented as autoimmune labyrinthitis, infective labyrinthitis, and other.


Based on the diagnosis, the market has been segmented as physical examination, blood test, magnetic resonance imaging and computed tomography, electroencephalogram (EEG) and electronystagmography (ENG) and others.


Based on the treatment, the market has been segmented as antihistaminics and antiemetics, antibiotics, corticosteroids, and others.


Based on the end user, the market has been segmented as hospitals & clinics, academic and research, and others.


Regional Analysis


The Americas accounts for a significant market share owing to high expenditure on the health care. Additionally, the fastest uptake of new diagnostics and drugs in the US drives the labyrinthitis market. Furthermore, concentration of the major healthcare companies and large hospitals in the developed countries of this region coupled with large insurance penetration are adding fuel to the market growth. The US expend high amount on its healthcare in 2015, which accounted for 16% of total GDP which, in turn, likely to drive the labyrinthitis market.


Europe is the second largest market in the world due to high income and strong healthcare penetration. The European market growth is led by countries such as Germany and France. The UK is expected to be the fastest growing market over the assessment period. However the southern European nations have witnessed a greater incidence of infective labyrinthitis due to associated environmental conditional. Owing to strong pharmaceutical industry, Germany dominates the Europe market.


Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. Furthermore, growing penetration of healthcare insurance in the Asia Pacific region is expected to drive the future labyrinthitis market in the region.


Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt, and Iran. The African region is expected to witness a moderate growth owing to poor economic and political conditions, and poor healthcare development. However the poor countries and developing regions have the greatest unmet needs, which needs to be tapped.


Key Players in the Global Labyrinthitis Market


Some of the key players profiled in the report are Merck & Co., Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eli Lilly and Company, Sun Pharmaceutical Industries Ltd., Shandong Taihua Bio &Tech Co., Cipla Inc., and others.

 



Frequently Asked Questions (FAQ) :


Labyrinthitis market is projected to grow at approximately 3.2 %CAGR during the assessment period (2017-2023).

Labyrinthitis market is estimated to reach a valuation of approx. USD 2.5 BN by the end of 2023.

The developments in the surgery segment such as minimal invasive laparoscopy surgery are the major tailwinds pushing the growth of the global Labyrinthitis market.

North America holds the largest share in the global labyrinthitis market, followed by Europe and the Asia Pacific, respectively.

Sanofi S.A., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Mylan N.V., Sun Pharmaceutical Industries Ltd., and Shandong Taihua Bio & Tech Co., Cipla Inc., are some of the top players operating in the global labyrinthitis market.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Labyrinthitis Market, by Types

6.1 Introduction

6.2 Autoimmune Labyrinthitis

6.2.1 Market Estimates & Forecast, 2017-2023

6.3 Infective Labyrinthitis

6.3.1 Market Estimates & Forecast, 2017-2023

6.4 Other

6.4.1 Market Estimates & Forecast, 2017-2023

7. Global Labyrinthitis Market, by Diagnosis

7.1 Introduction

7.2 Physical Examination

7.2.1 Market Estimates & Forecast, 2017-2023

7.3 Blood Test

7.3.1 Market Estimates & Forecast, 2017-2023

7.4 Magnetic Resonance Imaging and Computed Tomography

7.4.1 Market Estimates & Forecast, 2017-2023

7.4 Electroencephalogram (EEG) and Electronystagmography (ENG)

7.4.1 Market Estimates & Forecast, 2017-2023

7.5 Electroencephalogram (EEG) and Electronystagmography (ENG)

7.5.1 Market Estimates & Forecast, 2017-2023

8. Global Labyrinthitis Market, by Treatment

8.1 Introduction

8.2 Drugs

8.2.1 Market Estimates & Forecast, 2018-2023

8.3 Therapy

8.3.1 Market Estimates & Forecast, 2018-2023

8.4 Others

8.4.1 Market Estimates & Forecast, 2018-2023

9. Global Labyrinthitis Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

9.2.1 Market Estimates & Forecast, 2017-2023

9.3 Academic and Research Institutes

9.3.1 Market Estimates & Forecast, 2017-2023

9.4 Others

9.4.1 Market Estimates & Forecast, 2017-2023

10. Global Labyrinthitis Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 US

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 UK

10.3.1.4 Italy

10.3.1.5 Spain

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

12 Company Profiles

12.1 Merck & Co., Inc.

12.1.1 Overview

12.1.2 Product Overview

12.1.3 Financials

12.1.4 Key Developments

12.2 Sanofi S.A.

12.2.1 Overview

12.2.2 Product Overview

12.2.3 Financials

12.2.4 Key Developments

12.3 Teva Pharmaceutical Industries Ltd.

12.3.1 Overview

12.3.2 Product Overview

12.3.3 Financials

12.3.4 Key Development

12.4 Mylan Pharms Inc.,

12.4.1 Overview

12.4.2 Product Overview

12.4.3 Financials

12.4.4 Key Development

12.5 Eli Lilly and Company

12.5.1 Overview

12.5.2 Product Overview

12.5.3 Financials

12.5.4 Key Development

12.6 Sun Pharmaceutical Industries Ltd.

12.6.1 Overview

12.6.2 Product Overview

12.6.3 Financials

12.6.4 Key Development

12.7 Shandong Taihua Bio &Tech Co.

12.7.1 Overview

12.7.2 Product Overview

12.7.3 Financials

12.7.4 Key Development

12.8 Cipla Inc.

12.8.1 Overview

12.8.2 Product Overview

12.8.3 Financials

12.8.4 Key Development

12.9 Others

12.9.1 Overview

12.9.2 Product Overview

12.9.3 Financials

12.9.4 Key Development

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Labyrinthitis Treatment Industry

14 Appendix

List of Tables
TABLE 1 GLOBAL LABYRINTHITIS MARKET, BY TYPES, 2017-2023 (USD MILLION)

TABLE 2 AUTOIMMUNE LABYRINTHITIS FOR LABYRINTHITIS MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 3 INFECTIVE LABYRINTHITIS FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD

MILLION)

TABLE 4 OTHER MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 5 OTHER FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 6 GLOBAL LABYRINTHITIS MARKET, BY DIAGNOSIS, 2017-2023 (USD MILLION)

TABLE 7 PHYSICAL EXAMINATION FOR LABYRINTHITIS MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 8 BLOOD TEST FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 9 MAGNETIC RESONANCE IMAGING AND COMPUTED TOMOGRAPHY FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 10 ELECTROENCEPHALOGRAM (EEG) AND ELECTRONYSTAGMOGRAPHY (ENG) FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 11 OTHER FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 12 GLOBAL LABYRINTHITIS MARKET, BY TREATMENT, 2017-2023 (USD MILLION)

TABLE 13 DRUGS FOR LABYRINTHITIS MARKET, BY REGION, 2017-2023 (USD MILLION)

TABLE 14 THERAPY FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 15 OTHERS FOR LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 16 GLOBAL LABYRINTHITIS MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 17 NORTH AMERICA LABYRINTHITIS MARKET, BY COUNTRY 2017-2023 (USD MILLION)

TABLE 18 NORTH AMERICA LABYRINTHITIS MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 19 NORTH AMERICA LABYRINTHITIS MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 20 NORTH AMERICA LABYRINTHITIS MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 21 NORTH AMERICA LABYRINTHITIS MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 22 NORTH AMERICA LABYRINTHITIS MARKET BY REGION 2017-2023 (USD MILLION

TABLE 23 EUROPE LABYRINTHITIS MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 24 EUROPE LABYRINTHITIS MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 25 EUROPE LABYRINTHITIS MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 26 EUROPE LABYRINTHITIS MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 27 EUROPE LABYRINTHITIS MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 28 EUROPE LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 29 ASIA PACIFIC LABYRINTHITIS MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 30 ASIA PACIFIC LABYRINTHITIS MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 31 ASIA PACIFIC LABYRINTHITIS MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 32 ASIA PACIFIC LABYRINTHITIS MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 33 ASIA PACIFIC LABYRINTHITIS MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 34 ASIA PACIFIC LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET BY COUNTRY 2017-2023 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY TYPES 2017-2023 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY DIAGNOSIS 2017-2023 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY TREATMENT 2017-2023 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY END USER, 2017-2023 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY REGION 2017-2023 (USD MILLION)
List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET DYNAMICS FOR GLOBAL LABYRINTHITIS MARKET

FIGURE 3 GLOBAL LABYRINTHITIS MAKRET, BY SEGMENT, 2016

FIGURE 4 GLOBAL LABYRINTHITIS SUCCESS MARKET, BY REGION

FIGURE 5 GLOBAL LABYRINTHITIS MARKET SHARE, BY TYPES 2016

FIGURE 6 GLOBAL LABYRINTHITIS MARKET SHARE, BY DIAGNOSIS 2016

FIGURE 7 GLOBAL LABYRINTHITIS MARKET SHARE, BY TREATMENT 2016

FIGURE 8 GLOBAL LABYRINTHITIS MARKET SHARE, BY END USER, 2016

FIGURE 9 GLOBAL LABYRINTHITIS MARKET SHARE, 2016

FIGURE 10 GLOBAL LABYRINTHITIS MARKET SHARE, BY REGION, 2016

FIGURE 11 NORTH AMERICA LABYRINTHITIS MARKET SHARE, BY COUNTRY, 2016

FIGURE 12 EUROPE LABYRINTHITIS MARKET SHARE, BY COUNTRY, 2016

FIGURE 13 ASIA PACIFIC LABYRINTHITIS MARKET SHARE, BY COUNTRY, 2016

FIGURE 14 MIDDLE EAST & AFRICA LABYRINTHITIS MARKET, BY REGION, 2016

FIGURE 15 GLOBAL LABYRINTHITIS MARKET: COMPANY SHARE ANALYSIS, 2016 (%)

FIGURE 16 PFIZER INC.: KEY FINANCIALS

FIGURE 17 PFIZER INC.: SEGMENTAL REVENUE

FIGURE 18 PFIZER INC.: GEOGRAPHICAL REVENUE

FIGURE 19 NOVARTIS AG: KEY FINANCIALS

FIGURE 20 NOVARTIS AG: SEGMENTAL REVENUE

FIGURE 21 NOVARTIS AG: GEOGRAPHICAL REVENUE

FIGURE 22 MERCK & CO.: KEY FINANCIALS

FIGURE 23 MERCK & CO.: SEGMENTAL REVENUE

FIGURE 24 MERCK & CO.: GEOGRAPHICAL REVENUE

FIGURE 25 ELI LILLY AND COMPANY: KEY FINANCIALS

FIGURE 26 ELI LILLY AND COMPANY: SEGMENTAL REVENUE

FIGURE 27 ELI LILLY AND COMPANY: GEOGRAPHICAL REVENUE

FIGURE 28 SANOFI S.A.: FINANCIAL REVENUE

FIGURE 29 SANOFI S.A.: SEGMENTAL REVENUE

FIGURE 30 SANOFI S.A.: GEOGRPAHICAL REVENUE